Persistence of bactericidal antibodies following primary and booster MenACWY-TT vaccination of toddlers: A review of clinical studies. Issue 27 (2nd June 2020)

• Record Type: Journal Article
• Authors: Webber, Chris; Peyrani, Paula; Balmer, Paul; Serra, Lidia
• Is Part Of: Vaccine. Volume 38:Issue 27(2020)
• Page Start: 4236
• Page End: 4245
• Publication Date: 2020-06-02
• Subjects: Invasive meningococcal disease -- Vaccine -- Seroprotection -- Immunogenicity -- Antibody persistence -- Children -- Toddlers; GMT Geometric mean titer -- hSBA Serum bactericidal assay using human complement -- IMD Invasive meningococcal disease -- MenA Meningococcal serogroup A -- MenACWY Meningococcal serogroups A, C, W, and Y -- MenACWY-PS Quadrivalent meningococcal polysaccharide vaccine -- MenACWY-TT Quadrivalent meningococcal vaccine conjugated to tetanus toxoid as a carrier protein -- MenC Meningococcal serogroup C -- MenC-CRM Meningococcal serogroup C vaccine conjugated to the nontoxic form of diphtheria protein cross-reactive material 197 -- MenW Meningococcal serogroup W -- MenY Meningococcal serogroup Y -- MMRV Measles, mumps, rubella, varicella vaccine -- PHE Public Health England -- rSBA Serum bactericidal assay using baby rabbit complement; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2020.02.048
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: The long-term persistence of antibody responses following primary vaccination with quadrivalent conjugate vaccines targeting meningococcal serogroups A, C, W, and Y (MenACWY) and the duration of protection following a booster dose have not been fully elucidated, particularly in children who received primary dosing as toddlers. This review summarizes the findings of one phase 3 and three phase 2 open-label, randomized clinical studies that assessed the long-term antibody persistence of MenACWY conjugated to tetanus toxoid as a carrier protein (MenACWY-TT) in toddlers. Following primary vaccination, antibody responses persisted for approximately 2–3 years and then decreased up to 5 years after vaccination. Geometric mean titers remained elevated for all serogroups up to 5 years after primary vaccination. In children who received a booster dose of MenACWY-TT at 4–5 years after primary dosing as toddlers, antibody responses were documented in >99% of subjects across all serogroups, with minimal decreases in antibody persistence from 2–6 years after booster vaccination. The persistence of meningococcal serogroup C (MenC) antibody responses was similar between MenACWY-TT and MenC vaccine recipients after primary and booster dosing. Together, these findings indicate that antibody responses to primary MenACWY-TT vaccination persist for 2–3 years. Additionally, these findings indicate that in subjects who receive primary MenACWY-TT vaccination as toddlers, the antibody response to booster MenACWY-TT vaccination lasts for up to 6 years and suggest that immune memory is afforded at least into early adolescence, which is an age group at increased risk of invasive meningococcal disease.